Your session is about to expire
← Back to Search
Radiation Therapy
CyberKnife Stereotactic Radiosurgery for Non-Small Cell Lung Cancer
Phase 2
Waitlist Available
Research Sponsored by Accuray Incorporated
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 5 years
Awards & highlights
Study Summary
This trial will study the effectiveness of CyberKnife radiosurgery for early stage NSCLC in patients who are not healthy enough for surgery.
Eligible Conditions
- Non-Small Cell Lung Cancer
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 5 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~5 years
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Local progression-free survival, local disease progression, clinical response rate, regional recurrence-free survival, distant recurrence-free survival.
Secondary outcome measures
To characterize and compare quality of life before and after stereotactic radiosurgery treatment. To assess procedure-related outcomes after stereotactic radiosurgery of lung tumors.
Trial Design
1Treatment groups
Experimental Treatment
Group I: CyberKnife Stereotactic RadiosurgeryExperimental Treatment1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
CyberKnife Stereotactic Radiosurgery
2007
N/A
~380
Find a Location
Who is running the clinical trial?
Accuray IncorporatedLead Sponsor
9 Previous Clinical Trials
841 Total Patients Enrolled
University of PittsburghOTHER
1,729 Previous Clinical Trials
16,307,450 Total Patients Enrolled
James Luketich, MDStudy ChairUniversity of Pittsburgh Medical Center
2 Previous Clinical Trials
212 Total Patients Enrolled
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
Share this study with friends
Copy Link
Messenger